My ePortfolio Register   

Checkpoint inhibition in practice and in public

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.10.17
Views: 373

Dr Christy Ralph - St. James's Institute of Oncology, Leeds, UK

Dr Ralph speaks with ecancer at the ACP immunotherapy workshop about the implementation of checkpoint inhibitor therapy for cancer patients.

She notes successes for checkpoint therapy in different disease indications, and considers how clinical data from these may inform development for other diseases where checkpoint inhibitors have yet to improve outcomes.

Dr Ralph also considers the challenges facing the UK approvals agency NICE in managing availability and suitability of expensive drugs for sometimes rare disease or patient subtypes, and the role of doctors in communicating with, and on behalf of, patients when incomplete science enters public awareness.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence